
pmc: PMC2907940
Infection with the human immunodeficiency virus (HIV) usually leads to 8-10 years of asymptomatic infection before immune function deteriorates and AIDS develops. Without treatment, about 50% of infected people will die of AIDS over 10 years. With treatment, prognosis depends on age, CD4 cell count, and initial viral load.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of preventive interventions? What are the effects of different antiretroviral drug treatment regimens in HIV infection? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).We found 17 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.In this systematic review we present information relating to the effectiveness and safety of the following interventions: combination treatments containing either CCR5 inhibitors or fusion inhibitors; early diagnosis and treatment of sexually transmitted diseases (STDs); early and delayed antiretroviral treatment using triple antiretroviral regimens; non-nucleoside reverse transcriptase inhibitor (NNRTI) based triple regimens; nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor-based triple regimens (standard, and boosted); post-exposure prophylaxis in healthcare workers; and presumptive mass treatment of sexually transmitted diseases (STDs).
Cyclopropanes, Infectious Disease Transmission, Patient-to-Professional, Anti-HIV Agents, Sexually Transmitted Diseases, HIV Infections, HIV Protease Inhibitors, CD4 Lymphocyte Count, Benzoxazines, Early Diagnosis, Antiretroviral Therapy, Highly Active, Alkynes, Oxazines, Reverse Transcriptase Inhibitors, Humans, Drug Therapy, Combination, Nevirapine
Cyclopropanes, Infectious Disease Transmission, Patient-to-Professional, Anti-HIV Agents, Sexually Transmitted Diseases, HIV Infections, HIV Protease Inhibitors, CD4 Lymphocyte Count, Benzoxazines, Early Diagnosis, Antiretroviral Therapy, Highly Active, Alkynes, Oxazines, Reverse Transcriptase Inhibitors, Humans, Drug Therapy, Combination, Nevirapine
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
